CA2169635A1 - Methode, compositions et dispositifs pour administrer des polynucleotides nus codant des peptides biologiquement actifs - Google Patents

Methode, compositions et dispositifs pour administrer des polynucleotides nus codant des peptides biologiquement actifs

Info

Publication number
CA2169635A1
CA2169635A1 CA002169635A CA2169635A CA2169635A1 CA 2169635 A1 CA2169635 A1 CA 2169635A1 CA 002169635 A CA002169635 A CA 002169635A CA 2169635 A CA2169635 A CA 2169635A CA 2169635 A1 CA2169635 A1 CA 2169635A1
Authority
CA
Canada
Prior art keywords
polynucleotides
host
administration
compositions
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002169635A
Other languages
English (en)
Other versions
CA2169635C (fr
Inventor
Dennis A. Carson
Eyal Raz
Meredith L. Howell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2169635A1 publication Critical patent/CA2169635A1/fr
Application granted granted Critical
Publication of CA2169635C publication Critical patent/CA2169635C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205—Vaccinating by means of needles or other puncturing devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
CA002169635A 1993-08-26 1994-08-25 Methode, compositions et dispositifs pour administrer des polynucleotides nus codant des peptides biologiquement actifs Expired - Fee Related CA2169635C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11244093A 1993-08-26 1993-08-26
US08/112,440 1993-08-26
PCT/US1994/009661 WO1995005853A1 (fr) 1993-08-26 1994-08-25 Procede, compositions et dispositifs pour l'administration de polynucleotides nus qui codent des peptides a activite biologique

Publications (2)

Publication Number Publication Date
CA2169635A1 true CA2169635A1 (fr) 1995-03-02
CA2169635C CA2169635C (fr) 2002-11-12

Family

ID=22343912

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002169635A Expired - Fee Related CA2169635C (fr) 1993-08-26 1994-08-25 Methode, compositions et dispositifs pour administrer des polynucleotides nus codant des peptides biologiquement actifs

Country Status (6)

Country Link
EP (1) EP0714308A4 (fr)
JP (2) JPH09501936A (fr)
AU (1) AU705889B2 (fr)
CA (1) CA2169635C (fr)
MX (1) MX9406552A (fr)
WO (1) WO1995005853A1 (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0500799B1 (fr) 1989-11-16 1998-01-14 Duke University Transformation de cellules épidermales tissulaires animales à l'aide de particle
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
WO1998045408A2 (fr) * 1996-04-10 1998-10-15 Heska Corporation Nouvelles proteines de salive d'ectoparasite et appareil permettant de recueillir ces proteines
US20020169104A1 (en) 1997-05-01 2002-11-14 Glenn Frank Novel ectoparasite saliva proteins and apparatus to collect such proteins
GB9505777D0 (en) * 1995-03-22 1995-05-10 Zeneca Ltd Process
DE19512142A1 (de) * 1995-03-31 1996-10-02 Immuno Ag Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
GB9709900D0 (en) 1997-05-15 1997-07-09 Microbiological Res Authority Microencapsulated DNA for vaccination and gene therapy
EP0862419B2 (fr) 1995-11-09 2010-11-17 Microbiological Research Authority Adn microencapsule s'appliquant dans des procedes de vaccination et de therapie genique
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
WO1998008947A1 (fr) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Amelioration de l'immunisation a l'adn obtenu a l'aide de cytokines
EP0871747A1 (fr) * 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation a mediation par cellules dendritiques modifiees par des genes
ES2184990T3 (es) * 1996-02-12 2003-04-16 Ml Lab Plc Nuevos metodos de vacunacion y vacunas para los mismos que comprenden un acido nucleico que codifica un primer epitope y un peptido que contiene un segundo epitope.
US6689757B1 (en) 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
AU1865297A (en) * 1996-03-08 1997-09-22 University Of Toronto, The Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization
TW480282B (en) * 1996-04-24 2002-03-21 Ren Wen Corp Recombinant eucaryotic vector containing allergen gene and use of preventing and treating allergic disease thereof
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
EP0855184A1 (fr) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
WO1999008713A1 (fr) * 1997-08-13 1999-02-25 The Uab Research Foundation Vaccination par application topique de vecteurs genetiques
DE69837094T2 (de) 1997-09-05 2007-08-30 The Regents Of The University Of California, Oakland Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
WO1999036563A1 (fr) * 1998-01-14 1999-07-22 Emed Corporation Expression cellulaire a mediation electrique
JP2002502831A (ja) * 1998-02-03 2002-01-29 イネックス ファーマシューティカルズ コーポレイション 癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与
CA2323929C (fr) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Procedes et produits servant a stimuler le systeme immunitaire au moyen d'oligonucleotides et de cytokines immunotherapeutiques
JP4540845B2 (ja) * 1998-04-20 2010-09-08 トーレイ パインズ インスティテュート フォー モレキュラー スタディーズ ランゲルハンス細胞遊走を誘導する局所的免疫刺激
CA2328397A1 (fr) 1998-05-12 1999-11-18 Temple University - Of The Commonwealth System Of Higher Education Antithrombines iii humaines et procedes connexes
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
ATE256484T1 (de) * 1999-01-28 2004-01-15 Cyto Pulse Sciences Inc Einbringen von makromolekülen in zellen
US6335182B1 (en) * 1999-03-16 2002-01-01 Aventis Pasteur Limited Recombinant Haemophilus influenzae adhesin proteins
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
WO2002055559A1 (fr) * 2001-01-15 2002-07-18 Keryos Spa Vaccins a adn exprimant des determinants idiotypiques vh-cdr3 hypervariables
AU2002336760A1 (en) 2001-09-26 2003-06-10 Mayo Foundation For Medical Education And Research Mutable vaccines
GB0201736D0 (en) * 2002-01-25 2002-03-13 Glaxo Group Ltd DNA dosage forms
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003243381A1 (en) 2002-05-31 2003-12-19 University Of Utah Research Foundation Variants of antithrombin iii
US6946186B2 (en) 2002-08-24 2005-09-20 International Paper Co. Uncoated facestock for adhesive-backed labels
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2005080594A2 (fr) 2004-02-24 2005-09-01 Innogenetics N.V. Methode de determination des risques qu'a un sujet de contracter une maladie neurologique
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
WO2006079014A2 (fr) * 2005-01-21 2006-07-27 Introgen Therapeutics, Inc. Administration topique permettant l'exposition prolongee de cellules cibles a des acides nucleiques therapeutiques et prophylactiques
US7718622B2 (en) 2005-03-04 2010-05-18 Dynavax Technologies Corporation Compositions comprising structurally stable conjugate molecules
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CA2653628C (fr) 2006-06-01 2015-07-14 Elan Pharmaceuticals, Inc. Fragments neuroactifs de app
EP2118300B1 (fr) 2007-02-23 2015-05-27 Prothena Biosciences Limited Prévention et traitement de maladies synucléinopathiques et amyloïdogéniques
ES2546863T3 (es) 2007-02-23 2015-09-29 Prothena Biosciences Limited Prevención y tratamiento de enfermedad sinucleinopática y amiloidogénica
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
CA2971794C (fr) 2007-10-04 2020-03-24 Zymogenetics, Inc. Zb7h6 membre de la famille b7 et compositions et procedes apparentes
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009078799A1 (fr) 2007-12-17 2009-06-25 Marfl Ab Nouveau vaccin pour le traitement de troubles liés à une mycobactérie
EA036059B1 (ru) 2007-12-28 2020-09-21 Протена Байосайенсиз Лимитед Способ получения антитела или его фрагмента, которое специфически связывается с агрегированным амилоидным белком
MX2010014358A (es) 2008-06-20 2011-07-04 Wyeth Llc Composiciones y metodos de uso del orf1358 de cepas estreptococicas beta-hemoliticas.
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102281897A (zh) * 2008-10-31 2011-12-14 T·S·顾巴 通过机械破坏表皮进行痘病毒载体的疫苗接种
EP2580238A1 (fr) 2010-06-09 2013-04-17 Zymogenetics, Inc. Protéines de fusion vstm3 dimères et compositions et procédés connexes
DK2758433T3 (en) 2011-09-19 2018-01-15 Axon Neuroscience Se PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY OF ALZHEIMER'S DISEASE
KR101445560B1 (ko) 2012-05-10 2014-09-29 한국수력원자력 주식회사 저준위 전리방사선에 민감한 유전자 검출 방법 및 상기 방법으로 검출된 유전자
JP5917626B2 (ja) * 2014-07-28 2016-05-18 トレムアールエックス， インコーポレイテッド 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3596660A (en) * 1969-05-12 1971-08-03 Illinois Tool Works Injection device
AU570998B2 (en) * 1983-09-07 1988-03-31 Takeda Chemical Industries Ltd. Topical steroid compositions for acne
ATE165516T1 (de) * 1989-03-21 1998-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5157020A (en) * 1990-05-24 1992-10-20 Research Corporation Tech., Inc. Synthetic senescent cell antigen
NZ239274A (en) * 1991-08-05 1995-12-21 Zenith Technology Corp Ltd Scratch fluid medicament applicator for applying a vaccine to an animal
AU675702B2 (en) * 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material

Also Published As

Publication number Publication date
AU705889B2 (en) 1999-06-03
EP0714308A1 (fr) 1996-06-05
MX9406552A (es) 1997-02-28
CA2169635C (fr) 2002-11-12
WO1995005853A1 (fr) 1995-03-02
JP2004331668A (ja) 2004-11-25
JPH09501936A (ja) 1997-02-25
EP0714308A4 (fr) 1998-07-29
AU7639194A (en) 1995-03-21

Similar Documents

Publication Publication Date Title
CA2169635A1 (fr) Methode, compositions et dispositifs pour administrer des polynucleotides nus codant des peptides biologiquement actifs
TR199701071T2 (xx) Aktif madde ulaştırmaya mahsus bileşikler ve terkipler.
EP1090924B8 (fr) Peptides d'antigenes tumoraux provenant de la cyclophiline b
WO1999002186A3 (fr) Systeme d'administration d'antigene comprenant des derives de monoglyceride ou de diglyceride en tant qu'adjuvants
CA2203033A1 (fr) Composes et compositions pour l'administration d'agents actifs
EP1820862A3 (fr) Mise à l'échelle de polarisation de couple d'un côté sur l'autre afin d'améliorer la dérive dans une transmission à quatre roues motrices programmable
ES2020738A6 (es) Composiciones farmaceuticas comprendiendo ciclosporinas.
CA2180816A1 (fr) 6-dimethylaminomethyl-1-phenylcyclohexanes, principes actifs en pharmacie
CA2193337A1 (fr) Composes de type 1-phenyl-2-dimethylaminomethylcyclohexan-1-o1, ingredients pharmaceutiques actifs
CA2258811A1 (fr) Preparations servant a la prevention de maladies induites par des pathogenes tels que le vih ou le hsv
CA2241247A1 (fr) Archeosomes, archeosomes contenant la coenzyme q10, et autres types de liposomes contenant la coenzyme q10 utilises comme adjuvants et comme vehicules d'apport
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
WO1995013297A3 (fr) Compositions immunogenes ameliorees agissant contre la gastrine humaine 17
WO1994008551A3 (fr) Procedes et compositions pharmaceutiques destines au traitement des symptomes du rhume
CA2122058A1 (fr) Amelioration du developpement neuronal par le tgf-beta
AU7242796A (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
CA2169297A1 (fr) Vaccins a base de cochleate proteique ou peptidique et procedes d'immunisation faisant appel a ces vaccins
WO2003047500A3 (fr) Vaccin et methode de traitement de maladies du motoneurone
WO1994008613A3 (fr) Utilisation de parathormone, de ses fragments a activite biologique et de peptides associes pour le traitement de problemes de grossesse
BR9609871A (pt) Vacina de urease recombinante multimérica
WO1993019178A3 (fr) Peptides utilises pour l'induction de tolerance
WO1997042968A3 (fr) Administration d'histamine a des fins therapeutiques
CA2063416A1 (fr) Methodes de traitement et de prevention de l'uveoretinie chez les mammiferes
WO1995030435A3 (fr) Compositions et traitement de la sclerose en plaques
CA2327439A1 (fr) Therapie combinee pour le traitement de tumeurs

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed